Compass Therapeutics (CMPX) Amortization of Deferred Charges (2019 - 2026)
Compass Therapeutics (CMPX) posted Amortization of Deferred Charges of $353000.0 for Q1 2026, little changed sequentially from $353000.0 in Q4 2025, and up 57.59% YoY from $224000.0 in Q1 2025.
Compass Therapeutics (CMPX) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends
Compass Therapeutics has reported Amortization of Deferred Charges for 8 years, with the latest figure at $353000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges rose 57.59% year-over-year to $353000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 22.8% YoY) and the FY2025 annual result came in at $1.2 million, up 2.75% from the prior year.
- Amortization of Deferred Charges steadied at $353000.0 in Q1 2026 per CMPX's latest filing, from $353000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $353000.0 in Q4 2025 and troughed at $219000.0 in Q4 2024.
- A 5-year average of $295647.1 and a median of $295000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2024 and 2025: Amortization of Deferred Charges decreased 28.66% in 2024, then surged 61.19% in 2025.
- Over 5 years, Amortization of Deferred Charges stood at $289000.0 in 2022, then climbed by 6.23% to $307000.0 in 2023, then fell by 28.66% to $219000.0 in 2024, then soared by 61.19% to $353000.0 in 2025, then changed by 0.0% to $353000.0 in 2026.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $353000.0, $353000.0, and $352000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 355,000.00 |
| Jun 30, 2026 | 355,000.00 |
| Mar 31, 2026 | 353,000.00 |
| Mar 31, 2026 | 353,000.00 |
| Dec 31, 2025 | 353,000.00 |
| Dec 31, 2025 | 353,000.00 |
| Sep 30, 2025 | 352,000.00 |
| Sep 30, 2025 | 352,000.00 |
| Jun 30, 2025 | 267,000.00 |
| Jun 30, 2025 | 267,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Dec 31, 2024 | 219,000.00 |
| Dec 31, 2024 | 219,000.00 |
| Sep 30, 2024 | 322,000.00 |
| Sep 30, 2024 | 322,000.00 |
| Jun 30, 2024 | 314,000.00 |
| Jun 30, 2024 | 314,000.00 |
| Mar 31, 2024 | 309,000.00 |
| Mar 31, 2024 | 309,000.00 |